The olfactory receptor OR51E2 activates ERK1/2 through the Golgi-localized Gβγ-PI3Kγ-ARF1 pathway in prostate cancer cells.

Front Pharmacol

Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, GA, United States.

Published: October 2022

The olfactory receptor OR51E2 is ectopically expressed in prostate tissues and regulates prostate cancer progression, but its function and regulation in oncogenic mitogen-activate protein kinase (MAPK) activation are poorly defined. Here we demonstrate that β-ionone, an OR51E2 agonist, dose-dependently activates extracellular signal-regulated kinases 1 and 2 (ERK1/2) in prostate cancer cells, with an EC50 value of approximate 20 μM and an efficiency comparable to other receptor agonists. We also find that CRISPR-Cas9-mediated knockout of Golgi-translocating Gγ9 subunit, phosphoinositide 3-kinase γ (PI3Kγ) and the small GTPase ADP-ribosylation factor 1 (ARF1), as well as pharmacological inhibition of Gβγ, PI3Kγ and Golgi-localized ARF1, each abolishes ERK1/2 activation by β-ionone. We further show that β-ionone significantly promotes ARF1 translocation to the Golgi and activates ARF1 that can be inhibited by Gγ9 and PI3Kγ depletion. Collectively, our data demonstrate that OR51E2 activates ERK1/2 through the Gβγ-PI3Kγ-ARF1 pathway that occurs spatially at the Golgi, and also provide important insights into MAPK hyper-activation in prostate cancer.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606680PMC
http://dx.doi.org/10.3389/fphar.2022.1009380DOI Listing

Publication Analysis

Top Keywords

prostate cancer
16
olfactory receptor
8
receptor or51e2
8
or51e2 activates
8
activates erk1/2
8
gβγ-pi3kγ-arf1 pathway
8
cancer cells
8
prostate
5
or51e2
4
activates
4

Similar Publications

Background And Objective: PARP inhibitor (PARPi) treatment is an effective option for patients with metastatic castration-resistant prostate cancer (mCRPC). There are few data on the cardiovascular and thromboembolic safety of these agents in mCRPC, as cardiovascular and thromboembolic adverse events (AEs) are uncommon. Our aim was to analyze the incidence and risk of major adverse cardiovascular events (MACEs), thromboembolic events, and hypertension with PARPi therapy in mCRPC.

View Article and Find Full Text PDF

Background And Objective: MicroRNAs (miRNAs) are implicated in cancer by exerting roles in tumor growth, metastasis, and even drug resistance. The general trends of miRNA research in diverse cancers are not fully understood. In this work, miRNA-related research in colorectal cancer, prostate cancer, leukemia, and brain tumors was analyzed in search of key research trends with clinical potential.

View Article and Find Full Text PDF

Gut microbiota, metabolites, and cytokines in relation to the risk of prostate cancer in the Asian population.

Front Oncol

January 2025

Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.

Purpose: Studies have shown that gut microbiota is involved in the tumorigenesis and development of prostate cancer. We aimed to perform a comprehensive analysis of causal associations of gut microbiota, metabolites, and cytokines with prostate cancer in the Asian population.

Patients And Methods: Genome-wide association study (GWAS) summary datasets were collected from the public databases.

View Article and Find Full Text PDF

Purpose: Prostate-specific membrane antigen (PSMA) Positron emission tomography/magnetic resonance imaging (PET/MRI) surpasses conventional MRI (cMRI) in prostate cancer (PCa) evaluation. Our objective is to evaluate correlation of quantitative parameters in PCa using Fluorine-18 (F-18) PSMA-1007 PET/MRI and their potential for predicting metastases.

Methods: This retrospective study included 51 PCa patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!